Uncategorized Archives - Page 109 of 112

TuesdaySep 19, 2017 3:33 pm

At ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF), Medicinal Cannabinoid Quality and Safety are Founding Principles

Producer of consistent, standardized medicinal cannabis Menu of cannabis strains with varying CBD:THC ratios ABcann’s CBD-Med is one of Canada's highest-CBD products In an interview with Cantech Letter (http://cnw.fm/g2AtB), Aaron Keay, CEO of ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF), talked about the factors that triggered the genesis of the company, one of Canada’s trailblazing producers of medicinal cannabis. Ken Clement, the founder of ABcann, with his wealth of experience and knowledge, had observed the variability in consistency and potency of cannabis that was currently available. Although, in general, not much of a bother to recreational users, to those using cannabis…

ThursdaySep 14, 2017 2:31 pm

InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Builds Moat around Proprietary Biosynthesis Technology

Proprietary biosynthesis process to produce cannabinoids Provisional patent application filed Cost-effective methodology to produce trace cannabinoids If you have any doubt that InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) is on the right track as it moves to protect its biosynthesis technology for cannabinoids, then a word from a famed figure may make you change your mind. Known worldwide for his investing prowess, Warren Buffett has said, “I don't want a business that's easy for competitors. I want a business with a moat around it with a very valuable castle in the middle” (http://cnw.fm/ehB50). Naturally, the Sage of Omaha was…

WednesdaySep 13, 2017 3:58 pm

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Oral CBD Product to Be Tested by the University of British Columbia

The University of British Columbia (UBC) will conduct a double-blind study of Lexaria’s TurboCBD™ oral ingestion product TurboCBD™ masks foul tastes, protects pharmaceutical ingredients during stomach passage and increases intestinal absorption by 5-10x The UBC study will include 24 volunteers and test their cognitive and cardiovascular function after single doses and after seven days of administration Traditionally, cannabidiol (CBD) is ingested via inhalation, which can harm the lungs, and many edible products contain unwanted sugars or sweeteners. Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has revolutionized oral intake with its TurboCBD™ product. Engineered to increase absorption through the intestinal tract,…

ThursdaySep 07, 2017 2:14 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Continues Showcasing Proprietary Research at Cannabis Investment Conferences

Proprietary Lexaria technology improves delivery of bioactive compounds in a variety of products, including cannabis-based gourmet foods Market predictions for the legal marijuana industry forecast $50 billion in sales by 2026 19 patent applications filed and pending in more than 40 countries Following a successful showing at the inaugural Institutional Capital & Cannabis Conference (IC3) in California earlier this month, Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) CEO Chris Bunka expects the company to be noticed by investors. Bunka’s presentation of the company’s latest technology slated to benefit the cannabis industry includes the world’s first clinical study on human volunteers of…

ThursdayAug 31, 2017 3:34 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Begins Laboratory Venture with National Research Council

Collaborative venture could lead to strengthening of company’s patent portfolio, new commercial opportunities Firm receives patent in Australia, anticipates entering that market through cannabinoid licensing arrangements and product distribution partnerships LXRP names Allan Spissinger acting chief financial officer Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has begun laboratory work with the National Research Council ("NRC") (http://cnw.fm/Lp8bB). The collaboration will begin studies using LXRP’s patented technologies. The research will include the company’s technology in vitamins, NSAIDs, nicotine and cannabinoids utilizing lipophilic active agents. LXRP has patented technology involving how those agents are ingested into the human body in various edibles, such…

TuesdayAug 29, 2017 3:52 pm

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Ensuring Quality of Medical Cannabis Products with Proprietary Growing Technology

Environmentally-controlled growing chambers generate consistent, superior quality Proprietary technologies eliminate risk, ensuring patients enjoy peace of mind Publicly-traded ABcann entered funding deal for $15 million at $2.25 per share The Canadian government’s recent announcement that Broken Coast Cannabis Ltd. is recalling several products sold last year after two banned pesticides were found in random samples illustrates the importance of ABcann Global Corp.’s (TSX.V: ABCN) (OTCQB: ABCCF) controlled, pesticide-free approach to growing medical marijuana (http://nnw.fm/VM7zD). Several other cannabis-growing Canadian companies also reaped the attention of authorities following mandatory testing. Hydropothecary and Peace Naturals both had products recalled earlier this year following…

FridayAug 25, 2017 9:23 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Continues to Deliver Results with its Patented Technology

19 patent applications filed in the United States and internationally (under the Patent Cooperation Treaty), with national filings in 44 countries Collaborative research and development agreement with Canada’s National Research Council to investigate opportunities associated with bioavailability enhancement of certain compounds, including those in cannabinoids, vitamins, NSAIDs and nicotine Out-licenses its patented technology to third party partners, with several deals signed or pending When Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) researchers tackled the issue facing consumers of edible cannabinoids – poor absorption of the product’s bioactive compounds by the body’s gastrointestinal tract – an important statement led the way:…

ThursdayAug 24, 2017 3:22 pm

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Licensed to Grow Cannabis by Feds in Canada

An early mover in the Canadian cannabis space Serving Canada’s most populous province New funding deal signed for $15 million at $2.25 per share As befits its status as a first mover in the Canadian cannabis space, ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) is racing ahead with plans to supply the medical marijuana needs of Canada’s most populous province. Construction plans at its Kimmett facility in the third quarter of 2017 remain on schedule, and the previously announced plans for a 71,000 square foot phase 1 project have been expanded to 100,000 square feet. The company recently signed a…

MondayAug 14, 2017 5:00 pm

ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) Looks Strong for Investors in Booming Canadian Cannabis Market

ABcann’s low current market cap compared to similar companies offers an obvious opportunity for investors ABcann Global is one of Canada’s most dominant growers of medical marijuana and one of the growers to meet Canadian government’s stringent licensing requirements Major expansion of ABcann’s production capacity is underway An interesting opportunity for investors can be found in ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF), a Canadian grower of medical marijuana. ABcann recently acquired ABcann Medicinals and boasts a recent IPO, appointment of a new medical consultant, and major expansion plans. ABcann is new to the public market, having launched its initial…

MondayJul 24, 2017 12:06 pm

InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Aims at Future of Cannabinoid Compound Treatment

Specializing in novel cannabinoid drug therapies, InMed Pharmaceuticals is well-poised for cannabinoid research and development of new treatments Glaucoma and skin disease pharmaceuticals now in development have an estimated $7.6 billion potential market InMed Pharmaceutical’s chief medical officer helped $3 billion GW Pharmaceuticals develop one of the first cannabis-based drugs With its proprietary bioinformatics assessment tool, cannabinoid biosynthesis technology and drug development pipeline, InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) is well-positioned to target the future of cannabinoid pharmaceutical compounds. InMed is a pre-clinical stage biopharmaceutical company specializing in the development of novel therapies through research and development of the…

News and Publishing Service for Cannabis Related, Canadian Companies

Contact us: 512.354.7000

Category: Uncategorized